TD Cowen analyst Daniel Brennan maintained a Buy rating on Sera Prognostics (SERA – Research Report) today. The company’s shares closed today at $6.74.
According to TipRanks, Brennan is a 5-star analyst with an average return of 13.9% and a 49.81% success rate. Brennan covers the Healthcare sector, focusing on stocks such as 10x Genomics, Illumina, and Bruker.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sera Prognostics.
The company has a one-year high of $12.36 and a one-year low of $1.65. Currently, Sera Prognostics has an average volume of 87.48K.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SERA in relation to earlier this year. Last month, Mansoor Raza Mirza, a Director at SERA sold 96.00 shares for a total of $686.40.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Sera Prognostics (SERA) Company Description:
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications.
